Since SSADHD was first described in 1981, research has focused on identifying the spectrum of pathogenic ALDH5A1 mutations, understanding the molecular and biochemical basis of disease presentation, and testing promising therapeutics. The gene discussed is ALDH5A1; the disease is succinic semialdehyde dehydrogenase deficiency.